Innovative Blood Testing Tech Could Spell the End of Needle Phobia

Evestia Clinical’s Bold New Chapter in Oncology and Rare Disease Research

EMAS Pharma has officially rebranded as Evestia Clinical, signaling a bold new chapter as a specialised Contract Research Organization (CRO) dedicated to oncology and rare disease clinical trials. With the backing of Kester Capital and a leadership team with a proven track record, Evestia Clinical is set to redefine the clinical research landscape by delivering agile, expert-driven solutions to biotech innovators worldwide. With a rapidly growing demand for faster, more adaptive trials in complex therapeutic areas, this transformation comes at a critical time for the industry. The new identity underscores the company’s commitment to accelerating life-changing therapies to market while strengthening its strategic partnerships with biotech firms globally.

High Force Research Appoints Chief Commercial Officer to Drive Growth

High Force Research, a leading UK-based provider of specialist chemical R&D and manufacturing services has just appointed Dr. Nathalie Huther as its first-ever Chief Commercial Officer following a recent management buyout. This is a pivotal moment for the company, as it gears up to accelerate growth and deepen its presence in the pharmaceutical, biotech, and specialty chemicals markets. Nathalie brings 15+ years of commercial leadership experience across the chemical and life sciences sectors and will be steering High Force Research’s business development and market expansion strategy.

Phastar Secures Finalist Spot at 2025 Citeline Awards

Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health (MDGH), a not for profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most.

Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies

News from Cellistic, which has launched its new Echo™-NK platform to support the production of off-the-shelf Natural Killer cell therapies. The platform offers a cost-effective, GMP-compliant solution for scaling iPSC-derived NK cells, aimed at treating cancers and autoimmune diseases. It also integrates Cellistic’s STAR-CRISPR and Pulse technologies to help speed up development, with several client projects already in progress.

Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencing-Based Solutions

Cepheid and Oxford Nanopore Technologies announce new collaboration to develop an integrated sequencing workflow to advance infectious disease analysis.

Vaxess Announces $9M in Funding for Microarray Drug Delivery Platform

Vaxess Technologies, Inc., a biotech company developing a novel microarray patch technology to transform home delivery of therapies, today announced it has received an additional $9 million in funding. Investors included RA Capital Management and Engine Ventures.

Sphere Bio expands APAC distribution network to strengthen presence in region

Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today announced a significant expansion of its APAC distributor network. This development marks a key milestone in the Company’s global commercial strategy to meet growing demand for its next-generation single-cell analysis platforms.

Zymo Research Launches Research Grant to Empower Mapping the RNome

Our latest press release announces the launch of the RNome Disruptive Research Grant, a new funding opportunity designed to empower scientists exploring the complexities of RNA. We believe this development will be of significant interest to your audience, particularly those working in RNA research, genomics, molecular biology, and related fields. The press release highlights our commitment to advancing RNA science through a competitive grant that will award five researchers $5,000 USD each, along with a one-on-one consultation with our scientific team.

Indivumed Celebrates Milestone of Its Patient-Centric R&D Platform: Numerous Novel Cancer Targets Discovered for First-in-Class Therapeutics

Indivumed is proud to announce major milestones achieved, cementing its position as a leading oncology R&D company.

Integrated DNA Technologies and Elegen Partner to Revolutionize Long DNA Synthesis Market

Strategic partnership marks launch of early access program offering rapid, long, clonal gene synthesis and high-complexity genes up to 15 kb

New Research from eClinical Solutions Details Increased Focus on Risk-Based Strategies and Highlights AI Adoption Among Clinical Trial Leaders in 2025

Company prioritizes industry insights on key themes to transform clinical research through innovation in annual Industry Outlook report

AI Innovations in Laboratory Waste Management as UMass and Cornell Researchers Advance Recycling and Sustainable Plastics

Startup ProFuse Launches Pioneering Drug Discovery Platform for the Prevention of Muscle Loss

Israeli startup ProFuse has launched a new drug discovery platform to develop therapies that prevent muscle loss associated with GLP-1 weight-loss drugs, aging, and cancer. The platform uses lab-grown, highly mature human muscle tissues and automated screening to identify promising drug candidates, reducing reliance on animal testing and accelerating development timelines. The company also announced the appointment of veteran life sciences investor Anat Naschitz to its board.

Clearwater Publishes Cyber Risk Benchmark Trend Report for Healthcare Vulnerability Management

AES Cleanroom Technology introduces Omni ASCENT: a breakthrough in cleanroom utility integration at INTERPHEX 2025

United Laboratories Offers Up to $2B for Experimental Drug Rights; Novo Nordisk to Pay $2B in Milestones & Royalties

The Chinese pharmaceutical business United Laboratories International offered the Danish manufacturer up to $2 billion for the rights to an experimental medicine. In addition to tiered royalties, Novo Nordisk will make milestone payments of up to $1.8 billion and an upfront payment of $200 million.

CluePoints Appoints Usama Dar as Chief Product and Technology Officer

CluePoints, provider of leading statistical and AI-driven software solutions, has today announced Usama Dar as its new Chief Product and Technology Officer.

Association for Molecular Pathology Celebrates U.S. District Court’s Decision to Vacate FDA Rule on Laboratory-Developed Test Procedure Regulation

AMP announced a favorable ruling in its lawsuit against the U.S. FDA over the regulation of laboratory-developed test procedures.

Inspira Health Network Expands Utilization of the DoseMeRx Platform

DoseMe, a leading provider of model-informed precision dosing (MIPD), today announced Inspira has expanded the implementation of the dosing platform to serve the newly acquired Mannington site. Inspira has used DoseMeRx since 2020 and integrates with EHR software for faster, efficient access to patient profiles for overall better quality of care.